Identification of GPC2 as an oncoprotein and candidate immunotherapeutic target in high-risk neuroblastoma
We developed an RNA-sequencing-based pipeline to discover differentially expressed cell-
surface molecules in neuroblastoma that meet criteria for optimal immunotherapeutic target …
surface molecules in neuroblastoma that meet criteria for optimal immunotherapeutic target …
Immunotherapeutic targeting of GPC3 in pediatric solid embryonal tumors
Glypican 3 (GPC3) is a heparan sulfate proteoglycan and cell surface oncofetal protein
which is highly expressed on a variety of pediatric solid embryonal tumors including the …
which is highly expressed on a variety of pediatric solid embryonal tumors including the …
Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma
Neuroblastoma is a childhood cancer that is fatal in almost half of patients despite intense
multimodality treatment. This cancer is derived from neuroendocrine tissue located in the …
multimodality treatment. This cancer is derived from neuroendocrine tissue located in the …
Illuminating the Onco-GPCRome: Novel G protein–coupled receptor-driven oncocrine networks and targets for cancer immunotherapy
G protein–coupled receptors (GPCRs) are the largest gene family of cell membrane–
associated molecules mediating signal transmission, and their involvement in key …
associated molecules mediating signal transmission, and their involvement in key …
[HTML][HTML] GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity
Pediatric cancers often mimic fetal tissues and express proteins normally silenced
postnatally that could serve as immune targets. We developed T cells expressing chimeric …
postnatally that could serve as immune targets. We developed T cells expressing chimeric …
GPC2 is a potential diagnostic, immunological, and prognostic biomarker in pan-cancer
G Chen, D Luo, N Zhong, D Li, J Zheng, H Liao… - Frontiers in …, 2022 - frontiersin.org
Background Glypican 2 (GPC2), a member of glypican (GPC) family genes, produces
proteoglycan with a glycosylphosphatidylinositol anchor. It has shown its ascending …
proteoglycan with a glycosylphosphatidylinositol anchor. It has shown its ascending …
GPCRomics: GPCR expression in cancer cells and tumors identifies new, potential biomarkers and therapeutic targets
PA Insel, K Sriram, SZ Wiley, A Wilderman… - Frontiers in …, 2018 - frontiersin.org
G protein-coupled receptors (GPCRs), the largest family of targets for approved drugs, are
rarely targeted for cancer treatment, except for certain endocrine and hormone-responsive …
rarely targeted for cancer treatment, except for certain endocrine and hormone-responsive …
Next-generation cancer immunotherapy targeting glypican-3
Y Shimizu, T Suzuki, T Yoshikawa, I Endo… - Frontiers in …, 2019 - frontiersin.org
Glypican-3 (GPC3), a 65 kD protein consisting of 580 amino acids, is a heparan sulfate
proteoglycan bound to the cell membrane by glycosylphosphatidylinositol. This protein is …
proteoglycan bound to the cell membrane by glycosylphosphatidylinositol. This protein is …
[HTML][HTML] CAR T cells targeting tumor-associated exons of glypican 2 regress neuroblastoma in mice
Targeting solid tumors must overcome several major obstacles, in particular, the
identification of elusive tumor-specific antigens. Here, we devise a strategy to help identify …
identification of elusive tumor-specific antigens. Here, we devise a strategy to help identify …
High-affinity monoclonal antibodies to cell surface tumor antigen glypican-3 generated through a combination of peptide immunization and flow cytometry screening
Isolating high-affinity antibodies against native tumor antigens on the cell surface is not
straightforward using standard hybridoma procedures. Here, we describe a combination …
straightforward using standard hybridoma procedures. Here, we describe a combination …